Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C

Journal of Viral Hepatitis

Volumn 13, Issue 10, 2006, Pages 701-707

  Martinot Peignoux, M ^a   Comanor, L ^b   Minor, J M ^a   Ripault, M P ^a   Pham, B N ^c   Boyer, N ^a   Castelnau, C ^a   Giuily, N ^a   Hendricks, D ^a   Marcellin, Patrick ^a  

^a BEAUJON HOSPITAL   (France)

^b Agilent Technologies Inc ^*

^c BAYER CORPORATION   (United States)

Author keywords

Hepatitis C virus; Ordinal regression; Peginterferon 2b; SMILES; VERSANT HCV RNA qualitative and quantitative assays

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ACCURACY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; FIBROSIS; GENOTYPE; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME;

EID: 33747877887     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00750.x     Document Type: Article

References (21)

1. Berg T, Sarrazin C, Herrmann E et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37: 600-609.
2. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-652.
3. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
4. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
5. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36: S145-S151.
6. Neumann A, Schalm S, von Wagner M et al. Early viral kinetics prediction of sustained virological response after 1 or 4 weeks of PEG-interferon-alfa-2a and ribavirin therapy (DITTO HCV-project). Hepatology 2003; 38 (Suppl.): 248A (Abstract).
7. National Institutes of Health. Management of hepatitis C: 2002 NIH Consens State Sci Statements 2002; 19(3): 1-46. Accessed at: http://consensus.nih.gov/cons/116/116cdc_intro.htm.
8. Dhumeaux D, Marcellin P, Lerebours E. Treatment of hepatitis C. The 2002 French consensus. Gut 2003; 52: 1784-1787.
9. Elbeik T, Surtihadi J, Destree M et al. Multicenter evaluation of the performance characteristics of the Bayer VERSANT HCV RNA 3.0 assay (bDNA). J Clin Microbiol 2004; 42: 563-569.
10. Comanor L, Anderson F, Ghany M et al. Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. Am J Gastroenterol 2001; 96: 2968-2972.
11. Stuyver L, Rossau R, Wyseur A et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74: 1093-1102.
12. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.
13. Comanor L, Minor LM. Methods and apparatus for predicting therapeutic outcomes. US5860917A1, Chiron Corporation, 1999.
14. Minor JM, Namini H. Analysis of clinical data using neural nets. J Biopharm Stat 1996; 6: 83-104.
15. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: Who responds less well? Ann Intern Med 2004; 140: 370-381.
16. Martinot-Peignoux M, Marcellin P, Pouteau M et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-1056.
17. Martinot-Peignoux M, Boyer N, Pouteau M et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998; 29: 214-223.
18. Lee SS, Heathcote EJ, Reddy KR et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40 KD). J Hepatol 2002; 37: 500-506.
19. Marcellin P, Pouteau M, Martinot-Peignoux M et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995; 109: 156-165.
20. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
21. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.